Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04292223 · ClinicalTrials.gov registry record · Phase 4
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
A Phase 4 study of Parkinson Disease Psychosis, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
- 18
- Study locations
NCT04292223 is a Phase 4 study of Parkinson Disease Psychosis that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 29 participants. The trial reports 18 study locations across 11 states.
The verdict
NCT04292223, a Phase 4 study of Parkinson Disease Psychosis, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
- 18
- Study locations
Study Summary
To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis
Conditions Studied
Interventions
- DRUG Pimavanserin
Study Locations (18)
Florida
- Premier Clinical Research Institute, Inc. - Miami
- Global Health Research Center, Inc. - Miami Lakes
- Quantum Laboratories, Inc. - Pompano Beach
- Parkinson's Disease Treatment Center of Southwest Florida - Port Charlotte
- Accel Research Sites - Brain and Spine Institute - Port Orange
- Infinity Clinical Research, LLC - Sunrise
- Premiere Research Institute at Palm Beach Neurology - West Palm Beach
Ohio
- Neurology Diagnostics, Inc. - Dayton
- The Orthopedic Foundation - New Albany
Arizona
- Movement Disorders Center of Arizona - Scottsdale
California
- Neurology Center of North Orange County - Fullerton
Georgia
- AU Movement and Memory Disorders - Augusta
Maine
- Maine Medical Partners Neurology - Scarborough
New Hampshire
- Wentworth Health Partners Coastal Neurology Services - Dover
New Jersey
- Bio Behavioral Health - Toms River
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2020-02-10 |
| Est. Completion | 2022-04-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04292223
The ClinicalTrials.gov registry entry for NCT04292223 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease Psychosis appearing as the primary indexed condition, and to 1 intervention - of which Pimavanserin is the first listed.
NCT04292223 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Florida, Ohio, Arizona.
Frequently Asked Questions
What is clinical trial NCT04292223 about?
NCT04292223 is a clinical study titled "Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis". To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis
What is the current status of trial NCT04292223?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2020-02-10. Estimated completion is 2022-04-26.
What conditions does trial NCT04292223 study?
This clinical trial studies the following conditions: Parkinson Disease Psychosis.
What interventions are being tested in trial NCT04292223?
The interventions under investigation include: Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT04292223?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04292223 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Georgia, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease Psychosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.